386 related articles for article (PubMed ID: 1370313)
1. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
[TBL] [Abstract][Full Text] [Related]
3. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
4. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.
Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ
Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519
[TBL] [Abstract][Full Text] [Related]
5. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
Matsumoto M; Sugita Y; Seya T
Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
[TBL] [Abstract][Full Text] [Related]
6. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.
Fletcher A; Bryant JA; Gardner B; Judson PA; Spring FA; Parsons SF; Mallinson G; Anstee DJ
Immunology; 1992 Mar; 75(3):507-12. PubMed ID: 1374058
[TBL] [Abstract][Full Text] [Related]
7. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
Kuraya M; Yefenof E; Klein G; Klein E
Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
[TBL] [Abstract][Full Text] [Related]
8. Erythrocyte membrane protein deficiencies in paroxysmal nocturnal hemoglobinuria.
Schultz DR
Am J Med; 1989 Sep; 87(3N):22N-29N. PubMed ID: 2484793
[TBL] [Abstract][Full Text] [Related]
9. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
Iwata K; Seya T; Ariga H; Nagasawa S
J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
[TBL] [Abstract][Full Text] [Related]
10. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
Mold C; Walter EI; Medof ME
J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
[TBL] [Abstract][Full Text] [Related]
11. Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.
Roberts WN; Wilson JG; Wong W; Jenkins DE; Fearon DT; Austen KF; Nicholson-Weller A
J Immunol; 1985 Jan; 134(1):512-7. PubMed ID: 2578050
[TBL] [Abstract][Full Text] [Related]
12. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
Holguin MH; Wilcox LA; Bernshaw NJ; Rosse WF; Parker CJ
J Clin Invest; 1989 Nov; 84(5):1387-94. PubMed ID: 2478585
[TBL] [Abstract][Full Text] [Related]
13. Robust in vitro replication of Plasmodium falciparum in glycosyl-phosphatidylinositol-anchored membrane glycoprotein-deficient red blood cells.
Pattanapanyasat K; Walsh DS; Yongvanitchit K; Piyawatthanasakul N; Wanachiwanawin W; Webster HK
Am J Trop Med Hyg; 2003 Oct; 69(4):360-5. PubMed ID: 14640493
[TBL] [Abstract][Full Text] [Related]
14. Quantitative analysis of membrane cofactor protein (MCP) of complement. High expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation.
Seya T; Hara T; Matsumoto M; Akedo H
J Immunol; 1990 Jul; 145(1):238-45. PubMed ID: 1694203
[TBL] [Abstract][Full Text] [Related]
15. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
Pangburn MK; Schreiber RD; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5430-4. PubMed ID: 6225118
[TBL] [Abstract][Full Text] [Related]
16. Aberrant regulation of complement by the erythrocytes of hereditary erythroblastic multinuclearity with a positive acidified serum lysis test (HEMPAS).
Tomita A; Parker CJ
Blood; 1994 Jan; 83(1):250-9. PubMed ID: 7506081
[TBL] [Abstract][Full Text] [Related]
17. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
[TBL] [Abstract][Full Text] [Related]
18. Regulation of the alternative pathway of complement by pH.
Fishelson Z; Horstmann RD; Müller-Eberhard HJ
J Immunol; 1987 May; 138(10):3392-5. PubMed ID: 2952717
[TBL] [Abstract][Full Text] [Related]
19. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
Medof ME; Kinoshita T; Silber R; Nussenzweig V
Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
